Goldman Sachs
FDMT icon

Goldman Sachs’s 4D Molecular Therapeutics FDMT Stock Holding History

Goldman Sachs’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.2M Sell
4,205,438
-97,467
-2% -$848K ﹤0.01% 1776
2025
Q4 		$32.3M Buy
4,302,905
+174,489
+4% +$1.77M ﹤0.01% 1898
2025
Q3 		$35.9M Sell
4,128,416
-30,848
-0.7% -$184K ﹤0.01% 1696
2025
Q2 		$15.4M Sell
4,159,264
-9,130
-0.2% -$32.1K ﹤0.01% 2358
2025
Q1 		$13.5M Sell
4,168,394
-106,579
-2% -$502K ﹤0.01% 2409
2024
Q4 		$23.8M Buy
4,274,973
+683,943
+19% +$5.37M ﹤0.01% 1949
2024
Q3 		$38.8M Sell
3,591,030
-543,224
-13% -$9.01M 0.01% 1460
2024
Q2 		$86.8M Buy
4,134,254
+1,076,405
+35% +$27M 0.01% 870
2024
Q1 		$97.4M Buy
3,057,849
+2,241,506
+275% +$57.2M 0.02% 798
2023
Q4 		$16.5M Buy
816,343
+658,069
+416% +$8.66M ﹤0.01% 2084
2023
Q3 		$2.01M Sell
158,274
-35,991
-19% -$602K ﹤0.01% 3765
2023
Q2 		$3.51M Sell
194,265
-3,537
-2% -$65.1K ﹤0.01% 3414
2023
Q1 		$3.4M Buy
197,802
+79,458
+67% +$1.55M ﹤0.01% 3413
2022
Q4 		$2.63M Buy
118,344
+13,274
+13% +$205K ﹤0.01% 3714
2022
Q3 		$844K Sell
105,070
-28,493
-21% -$258K ﹤0.01% 4627
2022
Q2 		$932K Buy
133,563
+58,105
+77% +$565K ﹤0.01% 4671
2022
Q1 		$1.14M Buy
75,458
+41,963
+125% +$659K ﹤0.01% 4712
2021
Q4 		$735K Buy
33,495
+23,809
+246% +$584K ﹤0.01% 5090
2021
Q3 		$261K Buy
+9,686
New +$276K ﹤0.01% 5586
2021
Q2 		– Sell
-12,486
Closed -$542K – 6291
2021
Q1 		$542K Sell
12,486
-62,492
-83% -$2.77M ﹤0.01% 5056
2020
Q4 		$3.11M Buy
+74,978
New +$3.1M ﹤0.01% 3395

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Goldman Sachs's FDMT Position: Q1 2026 in Review

Goldman Sachs reduced its 4D Molecular Therapeutics (FDMT) stake by 2.3% in Q1 2026, selling an estimated $848K and leaving 4,205,438 shares worth $39.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1776.

Goldman Sachs first reported a position in FDMT in Q4 2020 and has held it in 21 quarters since. The position peaked at $97.4M in Q1 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Goldman Sachs held 4,205,438 shares of 4D Molecular Therapeutics worth $39.2M as of Q1 2026.
  • Goldman Sachs sold 97,467 4D Molecular Therapeutics shares in Q1 2026, an estimated $848K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #1776 holding.
  • Goldman Sachs first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Goldman Sachs's 4D Molecular Therapeutics position peaked at $97.4M in Q1 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.